Tag: S-ICD

Boston’s Empower leadless pacemaker demonstrates “excellent overall clinical performance” in MODULAR...

Boston Scientific recently announced late-breaking data from the MODULAR ATP clinical trial investigating the pacing performance of the company’s Empower leadless pacemaker. The data...

Novel extravascular substernal pacing as a feasible treatment option for arrhythmias

A study on substernal pacing acute clinical evaluation (SPACE) by Darius Sholevar (Our Lady of Lourdes Medical Center, Camden, USA) et al published in the...
bio envelope

New bio envelope designed for S-ICDs launches in USA

Aziyo Biologics has announced the launch of their CanGaroo bio envelope specifically for use with subcutaneous implantable cardioverter-defibrillators (S-ICDs). It is the only cardiac implantable...

S-ICD technology continues to advance rapidly

The benefits of the Subcutaneous Implantable Cardioverter Defibrillator (S-ICD, Boston Scientific) over transvenous (TV)-ICD, including lower rates of lead-related complications and lower in-hospital complication...

HRS 2017: S-ICDs successful despite a range of comorbidities, and across...

Initial real-world experience with the S-ICD (subcutaneous implantable cardioverter defibrillator) in the USA show that implant success rate is high and short-term complications acceptably...

Boston Scientific announces scheduled presentations at Heart Rhythm Society 2017

Boston Scientific has announced the schedule of key data presentations, including two late-breaking clinical trials that will be featured at the Heart Rhythm Society’s...

Modular cardiovascular device communication: A step towards artificial intelligence to treat...

The implantable cardioverter defibrillator (ICD) is a well-established therapy for the prevention of sudden cardiac death. However, it is still associated with complications over...

Acute and chronic performance of communicating leadless anti-tachycardia pacemaker and S-ICD

Martin Burke (CorVita Science Foundation, Chicago, USA) presents the preclinical acute and chronic performance of the combined implant of a leadless anti-tachycardia pacemaker and...

US FDA approves Boston Scientific Emblem MRI S-ICD system

Boston Scientific has received US Food and Drug Administration (FDA) approval for the Emblem MRI subcutaneous implantable defibrillator (S-ICD) system, as well as magnetic...

Boston Scientific receives CE mark for MRI labelling of Emblem S-ICD...

Boston Scientific has received CE mark approval for the new Emblem MRI subcutaneous implantable defibrillator (S-ICD) system, as well as magnetic resonance (MR) conditional labelling for all previously implanted Emblem S-ICD systems.

Boston Scientific initiates study to assess Emblem S-ICD in primary prevention...

The UNTOUCHED study will compare outcomes during an 18-month follow-up period to objective performance criteria derived from the MADIT-RIT study, which evaluated shock rates in 1,500 patients implanted with transvenous ICD devices.

Entirely Subcutaneous ICD (S-ICD) poised to revolutionise treatment of Sudden Cardiac...

The publication of important new long-term data from nearly 900 patients and a rapid evolution in the technology is putting entirely the Subcutaneous Implantable...